• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Which Hot Biotech Name Will Be Acquired Next?

Your burning biotech questions answered in our latest mailbag.
By BRET JENSEN
Mar 17, 2018 | 02:00 PM EDT
Stocks quotes in this article: MDVN, PFE, KITE, GILD, CELG, TSRO, CLVS, EXEL, BLUE

Let's go to to my Biotech Mailbag to answer two of the common questions we have received so far in March.

What Will It Take for Biotech to Break Out?

The main biotech indices are near highs they have not been able to decisively break above since late 2015. This was approximately half way through a bear market that took the sector down some 40% from peak to trough.

The sector has had a decent 2018 to date but is once again just below what have been strong resistance levels. Since I don't see a big rally in the cards for the overall market, something specific will have to happen for this high-beta part of the market to finally break through its current ceiling.

In my view, that would have to be the return of M&A across the industry. We had a good start to the year with some $30 billion of deals announced in the first five weeks of the year, but deals have been largely dormant since. Until we see transactions picking up again, the sector could remain in a trading range.

What Part of the Industry Is Ripe for Acquisitions?

I think the drug and pharma giants will pick up the pace of deals in the quarters ahead. They have clarity now thanks to tax reform and hundreds of billions of dollars from their overseas operations to "repatriate." They also have solid cash flow as well as an increasingly urgent need to replenish pipelines. Oncology has been one of the hottest sub-sectors in the industry for deals for quite some time. Medivation (MDVN) was acquired by Pfizer (PFE) in a bidding war for some $14 billion in August of 2016.

More recently Kite Pharma (KITE) was purchased by Gilead Sciences (GILD) for $12 billion late last summer which was followed by Celgene's (CELG) $9 billion deal for Juno Therapeutics JUNO to open this year. These were both in the emerging CAR-T space where Kite and Juno were two of the largest stand-alone plays.

The logical next "domino" to fall should be bluebird bio (BLUE) which has had a nice rally, in part because of the purchases of its brethren. However, Celgene has a huge collaboration with bluebird, which probably would scare off other likely suitors. I also think Celgene will spend some time digesting Juno before doing another significant acquisition.

Of the more traditional oncology plays, Tesaro (TSRO) , has been open to exploring strategic options. The stock is also seeing some major insider buying after a big recent decline in its shares. A likely acquirer might be concerned around slow initial sales of ZELUJA. I think Clovis Oncology (CLVS) is probably a more logical buyout target. The name also seems to near the top of every analyst firm's top potential biotech buyout list. In addition, they see a nice ramp up of indications Rubraca will be approved for in the years ahead.

Exelixis (EXEL) , whose drug Cabozantinib has taken market share much faster than initially expected, would be another potential logical target in the space.

This is an excerpt from Jensen's regular biotech mailbag column on Real Money Pro, our sister site for Wall Street professionals. Click here to check out more great columns from him, Doug Kass and other Real Money Pro writers.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Bret Jensen was Long CELG, CLVS, EXEL, GILD, TSRO.

TAGS: Investing | U.S. Equity | Healthcare | How-to | Mergers and Acquisitions | Stocks

More from Healthcare

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

CRISPR Therapeutics Has Turned the Corner

Bruce Kamich
Jul 1, 2022 8:43 AM EDT

Here's our current price target.

Johnson & Johnson Appears to Be Running Out of Steam

Bruce Kamich
Jun 22, 2022 8:25 AM EDT

The shares of the healthcare giant have been in a long-term uptrend but could break that trend in the weeks ahead.

Anthem's Long-Term Uptrend Is Losing Its Vigor

Bruce Kamich
Jun 22, 2022 7:40 AM EDT

The technical signals of the health benefits provider are weakening.

Here Are 2 Prudent Healthcare Trades

Bret Jensen
Jun 17, 2022 11:30 AM EDT

The country might be heading into recession, but folks still need to get their medicine, good times or bad.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:49 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Stop Wishing, Hoping, and Praying and Take Control...
  • 07:59 PM EDT PAUL PRICE

    Very Good Quarterly Numbers From Bassett Furniture (BSET)

    Bassett Furniture blew right through analysts es...
  • 04:41 PM EDT PAUL PRICE

    First-Half Results - Putrid; Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 mark...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login